Biomedica Immunoassays

First bioactive Sclerostin ELISA for clinical samples

02/13/2018

The only Sclerostin ELISA that utilizes specific EPITOPE MAPPED ANTIBODIES enabling the analysis of bioactive Sclerostin in clinical samples

Assay Highlights: 

√ HIGHLY SPECIFIC and DEFINED: capture antibody directed against Sclerostin's bioactive site
√ RELIABLE: human serum based calibrators and controls, rigorously validated
√ LOW SAMPLE VOLUME: 20 µl / well
√ QUICK: total incubation time 3.5 h

Areas of interest: osteoporosis, cancer induced bone diseases, rheumatoid arthritis, chronic inflammation, kidney diseases, therapy monitoring of anabolic treatment

For detailed information please click corresponding links: 

BI-20472 bioactive Sclerostin product website

BI-20472 bioactive Sclerostin ELISA IFU

BI-20472 bioactive Sclerostin ELISA Validation Data

BI-20472 bioactive Sclerostin ELISA MSDS 

Biomedica ELISA Service Quotation Form